NLS Pharmaceutics Schedules June 30th Annual Shareholder Meeting
Ticker: NCEL · Form: 6-K · Filed: Jun 10, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
NLS Pharmaceutics holding shareholder meeting June 30th, record date June 6th.
AI Summary
NLS Pharmaceutics Ltd. filed a Form 6-K on June 10, 2025, announcing its Annual General Shareholders' Meeting scheduled for June 30, 2025. Shareholders of record as of June 6, 2025, are eligible to vote at the meeting.
Why It Matters
This filing informs shareholders about the upcoming meeting where key corporate decisions will be made, impacting the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine corporate filing announcing a shareholder meeting, with no immediate financial or operational risks disclosed.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 30, 2025 (date) — Annual General Shareholders' Meeting date
- June 6, 2025 (date) — Record date for voting eligibility
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report the Notice of Meeting and Proxy Card for NLS Pharmaceutics Ltd.'s Annual General Shareholders' Meeting.
When is the Annual General Shareholders' Meeting scheduled to take place?
The Annual General Shareholders' Meeting is scheduled to be held on June 30, 2025.
Who is eligible to vote at the meeting?
Shareholders of record who hold common and/or preferred shares of the Registrant at the close of business on June 6, 2025, are eligible to vote.
What is the company's principal executive office address?
The company's principal executive office is located at The Circle 6, 8058 Zurich, Switzerland.
Does NLS Pharmaceutics file annual reports under Form 20-F or Form 40-F?
NLS Pharmaceutics files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 10, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).